AgenciesICICI Direct has buy call on PI Industries with a target price of Rs 3710. The current market price of is Rs 2960.2. Time period given by analyst is one year when . price can reach defined target.
PI Industries Ltd., incorporated in the year 1946, is a Large Cap company (having a market cap of Rs 45089.87 Crore) operating in Pesticides/Agro Chemicals sector.
PI Industries Ltd. key Products/Revenue Segments include Agri inputs, Export Incentives, Sale of services and Scrap for the year ending 31-Mar-2022.
Financials
For the quarter ended 30-06-2022, the company reported a Consolidated Total Income of Rs 1567.30 Crore, up 10.75 % from last quarter Total Income of Rs 1415.20 Crore and up 28.31 % from last year same quarter Total Income of Rs 1221.50 Crore. Company reported net profit after tax of Rs 258.50 Crore in latest quarter.
Investment Rationale
The brokerage expects better growth from CSM to continue for this quarter as well on the back of strong order backlog and decent demand from end industries. It expects topline to grow at 18% YoY to 1597.5crore. OPM can likely expand 65 bps YoY to 22.2% resulting in EBITDA growth of 21.5% YoY to Rs 354.9 crore. PAT is expected to grow 18.3% YoY to Rs 271.7 crore. Key monitorable: Development of key molecules in pharma intermediates
Promoter/FII Holdings
Promoters held 46.74 per cent stake in the company as of 31-Mar-2022, while FIIs owned 23.1 per cent, DIIs 18.66 per cent.
PI Industries Ltd., incorporated in the year 1946, is a Large Cap company (having a market cap of Rs 45089.87 Crore) operating in Pesticides/Agro Chemicals sector.
PI Industries Ltd. key Products/Revenue Segments include Agri inputs, Export Incentives, Sale of services and Scrap for the year ending 31-Mar-2022.
Financials
For the quarter ended 30-06-2022, the company reported a Consolidated Total Income of Rs 1567.30 Crore, up 10.75 % from last quarter Total Income of Rs 1415.20 Crore and up 28.31 % from last year same quarter Total Income of Rs 1221.50 Crore. Company reported net profit after tax of Rs 258.50 Crore in latest quarter.
Investment Rationale
The brokerage expects better growth from CSM to continue for this quarter as well on the back of strong order backlog and decent demand from end industries. It expects topline to grow at 18% YoY to 1597.5crore. OPM can likely expand 65 bps YoY to 22.2% resulting in EBITDA growth of 21.5% YoY to Rs 354.9 crore. PAT is expected to grow 18.3% YoY to Rs 271.7 crore. Key monitorable: Development of key molecules in pharma intermediates
Promoter/FII Holdings
Promoters held 46.74 per cent stake in the company as of 31-Mar-2022, while FIIs owned 23.1 per cent, DIIs 18.66 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
Read More News on
(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
Pick the best stocks for yourself
Powered by